טוען...
Escape or Fight: Inhibitors in Hemophilia A
Replacement therapy with coagulation factor VIII (FVIII) represents the current clinical treatment for patients affected by hemophilia A (HA). This treatment while effective is, however, hampered by the formation of antibodies which inhibit the activity of infused FVIII in up to 30% of treated patie...
שמור ב:
| הוצא לאור ב: | Front Immunol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7105606/ https://ncbi.nlm.nih.gov/pubmed/32265927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00476 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|